echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The Lancet sub-issue: FIRST-line treatment or change of AIDS WHO commissioned research to update evidence

    The Lancet sub-issue: FIRST-line treatment or change of AIDS WHO commissioned research to update evidence

    • Last Update: 2020-10-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A major study published recently in the Lancet journal EClinical Media supports dolutegravir as a first-line treatment for newly diagnosed people living with HIV.
    study, commissioned by the World Health Organization (WHO), is intended to provide insight into the update of the HIV Antiretroviral Therapy (ART) Guidelines Program.
    results will drive changes to first-line treatment recommendations for newly diagnosed HIV-infected patients, which will affect about 2 million people worldwide each year.
    screenshot source: EClinical Media 2016, WHO guidelines refer to research showing that dorutwe is effective and well-to-bear, but there is a lack of information on efficacy and safety in pregnant women and in patients with combined TB.
    since then, there have been studies suggesting that the treatment of pregnant women may increase the risk of neural tube defects in newborns.
    international guidelines, due to concerns about unknown risks, Dorutwe is used only as an alternative to the first-line antiviral drug efavirenz.
    to update the evidence, this systematic review and meta-analysis included clinical trial data for 68 antiretroviral first-line therapies.
    results, it is found that in the virus suppression, tolerance and safety and other aspects, Dorutwe is better than the legal Weilun.
    , for example, the chances of dolutway suppressing the virus nearly doubled in week 96.
    means that more patients who initiate treatment are expected to successfully control the virus in their bodies, which has a significant impact on the achievement of HIV treatment goals.
    Kanters of the University of British Columbia, author of the study.
    therapy, the comparison of virus suppression between different therapies over time.
    DTG is Dorutwe and EFV is Legal Wellen.
    key information from the NNRTI antiretroviral drug ( e.g. legally viron) is that dorutvir is still valid in patients who are already resistant to the drug.
    study, the risk of drug resistance was 87 percent lower than in the legal veylon, and patient compliance was better and the risk of drug breaks was 42 percent lower.
    analysis also showed that in pregnant women, the rate of adverse events in Dorutwe and Legal Wellen was similar, and the risk of neural tube defects caused by Dorutwe increased by less than 0.3%.
    Kanters said: "The new evidence suggests that Dr. Dorutwe is much better to use than previously thought.
    , the
    paper notes, the evidence supports the use of lamivudine/emtricitabine and tenofovir disoproxil fumarate as preferred first-line treatment options.
    Kanters also cautioned,
    I just as important is to recognize the achievements of legal veren over the past two decades, and with the widespread use of this drug, the use of antiretroviral therapy worldwide is expanding."
    " References, Steve Kanters, et al., (2020). Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A system literature review and network meta-analysis. EClinical Mediaine, DOI: New research comparing HIV treatments set to change international recommendations. Retrieved October 19, 2020, from
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.